Aurobindo Pharma Limited (NSE:AUROPHARMA)
1,239.30
+2.40 (0.19%)
Nov 18, 2025, 3:29 PM IST
Aurobindo Pharma Revenue
Aurobindo Pharma had revenue of 82.86B INR in the quarter ending September 30, 2025, with 6.28% growth. This brings the company's revenue in the last twelve months to 325.14B, up 7.33% year-over-year. In the fiscal year ending March 31, 2025, Aurobindo Pharma had annual revenue of 317.24B with 9.39% growth.
Revenue (ttm)
325.14B
Revenue Growth
+7.33%
P/S Ratio
2.21
Revenue / Employee
11.74M
Employees
27,707
Market Cap
719.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 317.24B | 27.22B | 9.39% |
| Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
| Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
| Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
| Mar 31, 2021 | 247.75B | 16.76B | 7.26% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Glenmark Pharmaceuticals | 161.53B |
| Biocon | 155.12B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
Aurobindo Pharma News
- 4 days ago - Aurobindo Pharma receives US FDA clearance for Unit-I; Warning letter officially closed - Business Upturn
- 11 days ago - [Brokerage calls] Top stocks to watch on November 7: Cummins, UPL, Lupin, Aurobindo Pharma among key brokerage picks - Business Upturn
- 12 days ago - Aurobindo Pharma Ltd (BOM:524804) Q2 2026 Earnings Call Highlights: Strong European Growth and ... - GuruFocus
- 12 days ago - Q2 2026 Aurobindo Pharma Ltd Earnings Call Transcript - GuruFocus
- 13 days ago - Top stocks to watch today, November 6: TCS, Paytm, M&M, RBL Bank, Britannia Industries, Aurobindo Pharma and more - Business Upturn
- 13 days ago - Top Q2 results today, November 5: Aurobindo Pharma, Blue Star, Delhivery, Zydus Wellness more to announce earnings - Business Upturn
- 22 days ago - Aurobindo Pharma shares rise as US FDA concludes issues at Hetero Labs’ Vishakhapatnam warehouse - Business Upturn
- 26 days ago - Aurobindo Pharma expands global footprint, incorporates new subsidiary in Chile to strengthen Latin American presence - Business Upturn